A Prospective Study of Adequacy of Anticoagulation with Fixed Dose Weight Adjusted Unfractionated Heparin in Patients with Deep Vein Thrombosis

详细信息    查看全文

• 作者：Subash Chandra Bose ; Rakhee Kar…
• 关键词：Deep vein thrombosis ; Pulmonary embolism ; Anticoagulation ; Unfractionated heparin
• 刊名：Indian Journal of Hematology and Blood Transfusion
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：32
• 期：1
• 页码：83-86
• 全文大小：359 KB
• 参考文献：1.Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS (1998) Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 279:458–462CrossRef PubMed
  2.Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B et al (1991) A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 151:933–938CrossRef PubMed
  3.Lee LH, Gu KQ, Heng D (2002) Deep vein thrombosis is not rare in Asia–the Singapore General Hospital experience. Ann Acad Med Singap 31:761–764PubMed
  4.Cushman M (2013) Treating acute venous thromboembolism—shift with care. N Engl J Med 369:865–866CrossRef PubMed
  5.Goldhaber SZ, Bounameaux H (2012) Pulmonary embolism and deep vein thrombosis. Lancet 379:1835–1846CrossRef PubMed
  6.Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ et al (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e419S–e494SPubMedCentral CrossRef PubMed
  7.Kearon C, Ginsberg JS, Julian JA, Douketis J, Solymoss S, Ockelford P et al (2006) Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 296:935–942CrossRef PubMed
  8.Kearon C, Harrison L, Crowther M, Ginsberg JS (2000) Optimal dosing of subcutaneous unfractionated heparin for the treatment of deep vein thrombosis. Thromb Res 97:395–403CrossRef PubMed
  9.Munsamy JI, Kertland H, Parrish A (2010) Validation of a dosing regimen for fixed-dose, weight-adjusted, subcutaneous unfractionated heparin for the acute treatment of venous thrombo-embolism in a population from a resource-constrained environment. South Afr Med J 100:432–434
  10.Garcia DA, Baglin TP, Weitz JI, Samama MM (2012) Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e24S–e43SPubMedCentral CrossRef PubMed
  
• 作者单位：Subash Chandra Bose (1)
  Rakhee Kar (2)
  Suryanarayana Bettadpura Shamanna (1)
  
  1. Department of Medicine, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, 605006, India
  2. Department of Pathology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, 605006, India
  
• 刊物主题：Hematology; Oncology; Blood Transfusion Medicine; Human Genetics;
• 出版者：Springer India
• ISSN：0974-0449

文摘

Weight adjusted fixed dose subcutaneous unfractionated heparin (UFH) is one of the options for the treatment of deep vein thrombosis (DVT), but the degree of its anticoagulant effect has not been tested in India. This was a prospective observational study, conducted at a tertiary care hospital in South India between September 2012 and March 2014. DVT was diagnosed using compression ultrasonography. UFH was given as an initial loading dose of 333 U/kg followed by a maintenance dose of 250 U/kg twice daily subcutaneously. aPTT was done on day 2 and day 4 after 6 h of the morning dose of heparin. Patients were categorized based on aPTT ratios. Fifty five patients treated for proximal lower limb DVT had received UFH. Their median age was 41 years. DVT was secondary to malignancy, immobilisation or pro-coagulant state. No obvious etiology was found in 47 % of the patients. The mean aPTT on day 2 was 41.8 s and 51.7 s on day 4. The aPTT ratio was subtherapeutic in 63.6 % and therapeutic in 32.7 % of the patients on day 2. Five patients had adverse events in the hospital. Three patients died and two other patients had confirmed pulmonary embolism. Death was due to pulmonary embolism in one patient and metastatic malignancies in the other two. No bleeding manifestation had occurred. Caution is required in implementing this UFH regimen as this preliminary investigation has found predominantly subtherapeutic aPTT ratios during the initial phase of anticoagulation. Keywords Deep vein thrombosis Pulmonary embolism Anticoagulation Unfractionated heparin